We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Libtayo Medison Pharma Australia Pty Ltd
Product name
Libtayo
Sponsor
Accepted date
Apr-2026
Active ingredients
cemiplimab
Summary of proposed indication
LIBTAYO (cemiplimab) as monotherapy is proposed for the adjuvant treatment of patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery.
Application type
C (new indication)
Publication date
Apr-2026